Approved (Dupixent) for adolescents aged 12 to 17 years with moderate-to-severe… not advisable.
A biologic antibody targeted against specific lymphocytes that are upregulated in eczema.
Acts more like an immune correcting agent rather than immune suppressing drug.
Tradename Dupixent.
Can be used with or without topical corticosteroids.
Is a targeted biologic therapy that inhibits interleukin-4 and interleukin-13, which may play a central role in type 2 inflammation involved in atopic dermatitis and other allergic diseases.
Its average improvement from baseline in the Eczema Area and Severity Index (EASI) score is roughly 66% compared with 24% with placebo.
24% of patients treated with dupilumab achieved clear or almost clear skin compared with just 2% of patients treated with placebo.
42% of patients achieved 75% or greater skin improvement with dupilumab versus 8% with placebo.
37% of patients treated with dupilumab achieved a clinically meaningful improvement in itch compared with 5% with placebo.
Safety profile in adolescents is similar to that in adults.
The most common adverse events were injection-site reactions, eye and eyelid inflammation including redness, swelling and itching, oropharyngeal pain, and cold sores in the mouth or on the lips.
It comes in two dose subcutaneous injections 200 mg and 300 mg, each as a prefilled syringe.
It is administered every other week following an initial loading dose.